Korea Business News Agency - NSP NEWS.

(Seoul=NSP NEWS AGENCY) = HK inno.N's new drug for gastroesophageal reflux disease, K-Cab, is expected to enter the Australian and New Zealand markets, leading to expectations for good performance.

HK inno.N announced, “We recently signed a contract with Australian pharmaceutical company Southern XP to export finished products of K-Cab Tab.(ingredient name: Tegoprazan), the new drug for gastroesophageal reflux disease, to Australia and New Zealand.”

Under this agreement, Southern XP has exclusive distribution and sales rights for K-Cab. The pharmaceutical market in Australia and New Zealand is worth about KRW 22 trillion as of 2023. Of this, the market for peptic ulcer drugs is worth about KRW 150 billion.

According to HK inno.N, K-Cab is a new drug in the P-CAB series for gastroesophageal reflux disease. Its characteristics include rapid onset of effect within 1 hour after administration and secured efficacy and safety even with long-term use of up to 6 months.

K-Cab has been launched in 15 countries, including 48 countries around the world, including Korea, the US, and China. In Korea, it has recorded a total of KRW 177.7 billion in outpatient prescription sales from January to November 2024, ranking first in the domestic peptic ulcer treatment market for five consecutive years.

By Soon-ki Lee(s8789@nspna.com) and Bombyeot Lee(leebb@nspna.com)

ⓒNSP News Agency·NSP TV. All rights reserved. Prohibits using to train AI models.